Replies to post #125038 on Biotech Values

[EYEBUYSTOX]

That 22 million is a drop in the bucket compared to what they would need to be a juggernaut.

With such a small market cap, they don't need to be a juggernaut for FCSC to deliver substantial shareholder value over the next 12 months. If and when LaViv is accepted by consumers, this stock should appreciate well. The FDA approval is in hand and $22 million is in the bank. Now we wait to see if the public is accepting of an autologous cell therapy for wrinkles. It would only take a fraction of the multi-billion cosmetic market to make FCSC a winner. JMHO